Growth Metrics

Biogen (BIIB) Cash from Investing Activities (2016 - 2026)

Biogen has reported Cash from Investing Activities over the past 18 years, most recently at -$209.5 million for Q1 2026.

  • For Q1 2026, Cash from Investing Activities fell 342.92% year-over-year to -$209.5 million; the TTM value through Mar 2026 reached -$1.5 billion, down 96.45%, while the annual FY2025 figure was -$1.4 billion, 71.56% down from the prior year.
  • Cash from Investing Activities for Q1 2026 was -$209.5 million at Biogen, up from -$1.2 billion in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $1.7 billion in Q3 2022 and troughed at -$1.7 billion in Q3 2023.
  • A 5-year average of -$288.5 million and a median of -$141.1 million in 2022 define the central range for Cash from Investing Activities.
  • Biggest five-year swings in Cash from Investing Activities: skyrocketed 815.84% in 2022 and later crashed 6522.04% in 2025.
  • Year by year, Cash from Investing Activities stood at -$141.1 million in 2022, then crashed by 362.3% to -$652.3 million in 2023, then soared by 97.15% to -$18.6 million in 2024, then crashed by 6522.04% to -$1.2 billion in 2025, then soared by 82.99% to -$209.5 million in 2026.
  • Business Quant data shows Cash from Investing Activities for BIIB at -$209.5 million in Q1 2026, -$1.2 billion in Q4 2025, and -$35.1 million in Q3 2025.